These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29968698)

  • 1. Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation.
    Verschelden G; Van Laethem J; Velkeniers B; Ilsen B; Noeparast A; De Grève J
    Pol Arch Intern Med; 2018 Jun; 128(6):386-388. PubMed ID: 29968698
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).
    Cohen Aubart F; Emile JF; Carrat F; Charlotte F; Benameur N; Donadieu J; Maksud P; Idbaih A; Barete S; Hoang-Xuan K; Amoura Z; Haroche J
    Blood; 2017 Sep; 130(11):1377-1380. PubMed ID: 28667012
    [No Abstract]   [Full Text] [Related]  

  • 3. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
    Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
    Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
    Cohen Aubart F; Emile JF; Maksud P; Galanaud D; Cluzel P; Benameur N; Aumaitre O; Amoura Z; Haroche J
    Br J Haematol; 2018 Jan; 180(1):150-153. PubMed ID: 27711968
    [No Abstract]   [Full Text] [Related]  

  • 5. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers.
    Ruan GJ; Goyal G; Shah MV; Cohen-Aubart F; Amoura Z; Straetmans N; Benameur N; Haroche J; Go RS;
    Pancreas; 2021 Jan; 50(1):e6-e8. PubMed ID: 33370037
    [No Abstract]   [Full Text] [Related]  

  • 7. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
    Yuen CA; Bao S; Aung MS; Shishodia R; Kong XT
    Per Med; 2024; 21(2):71-78. PubMed ID: 38275171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.
    Roeser A; Cohen-Aubart F; Breillat P; Miyara M; Emile JF; Charlotte F; Donadieu J; Amoura Z; Haroche J
    Haematologica; 2019 Nov; 104(11):e502-e505. PubMed ID: 30923093
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term follow-up of mTOR inhibition for Erdheim-Chester disease.
    Pegoraro F; Maniscalco V; Peyronel F; Westenend PJ; Hendriksz TR; Roperto RM; Palumbo AA; Sieni E; Romagnani P; van Bommel EFH; Vaglio A
    Blood; 2020 May; 135(22):1994-1997. PubMed ID: 32299103
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in Understanding and Management of Erdheim-Chester Disease.
    Kulkarni AM; Gayam PKR; Aranjani JM
    Life Sci; 2024 Jul; 348():122692. PubMed ID: 38710283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erdheim-Chester disease harboring the BRAF V600E mutation.
    Blombery P; Wong SQ; Lade S; Prince HM
    J Clin Oncol; 2012 Nov; 30(32):e331-2. PubMed ID: 23008323
    [No Abstract]   [Full Text] [Related]  

  • 12. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
    Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
    J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.
    Salama H; Fahed Alzayed M; Alharbi KG; Khattak Z; Omer MH; Tahir L; ALhejazi A
    Am J Case Rep; 2022 Feb; 23():e935090. PubMed ID: 35171900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
    Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M
    Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypoalphalipoproteinemia and BRAF
    Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.
    Wilgenhof S; Neyns B
    J Clin Oncol; 2015 Oct; 33(28):e109-11. PubMed ID: 24733801
    [No Abstract]   [Full Text] [Related]  

  • 17. Erdheim-Chester Disease With Cardiovascular Involvement and BRAF V600E Mutation.
    Okamura K; Suematsu Y; Morizumi S; Kawata M; Dai Y; Yamakawa M; Ono M
    Circ J; 2016 Jun; 80(7):1657-9. PubMed ID: 27296272
    [No Abstract]   [Full Text] [Related]  

  • 18. Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder.
    Bosco J; Allende A; Varikatt W; Lee R; Stewart GJ
    Intern Med J; 2015 Mar; 45(3):348-51. PubMed ID: 25735579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-RAF
    Sugaya T; Kanno H; Matsuda M; Handa K; Tateda S; Murakami T; Ozawa H; Itoi E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcoidosis occurring during BRAF/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients.
    Amoura A; Haroche J; Emile JF; Barete S; Helias-Rodzewicz Z; Charlotte F; Maisonobe T; Amoura Z; Cohen Aubart F
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e348-e350. PubMed ID: 31002424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.